Organometallic Iridium Complexes with Glucose Based Phosphite Ligands

被引：2

作者：

Gonchar, Maria R. ^{[1
]}

Ninin, Fedor S. ^{[1
]}

Mazur, Dmitrii M. ^{[1
]}

Lyssenko, Konstantin A. ^{[1
,2
]}

Milaeva, Elena R. ^{[1
]}

Nazarov, Alexey A. ^{[1
]}

机构：

[1] Moscow MV Lomonosov State Univ, Dept Chem, Leninskie Gory 1-3, Moscow 119991, Russia

[2] GV Plekhanov Russian Univ Econ, Basic Dept Chem Innovat Mat & Technol, 36 Stremyanny Per, Moscow 117997, Russia

来源：

INORGANICS | 2023年 / 11卷 / 03期

基金：

俄罗斯基础研究基金会;

关键词：

iridium complexes; phosphite ligands; antiproliferative activity; RUTHENIUM COMPLEXES; ANTICANCER DRUGS; CHEMISTRY; DESIGN; DNA;

D O I：

10.3390/inorganics11030124

中图分类号：

O61 [无机化学];

学科分类号：

070301 ; 081704 ;

摘要：

New organometallic iridium compounds with phosphorus modified glucose ligands containing isopropylidene protection group or bearing uracil, thymine, and 5-fluorouracil (3,5,6-bicyclophosphite-1,2-O-isopropylidene-alpha-d-glucofuranoside, 3,5,6-bicyclophosphite-1-beta-D-glucofuranosyluracil, 3,5,6-bicyclophosphite-1-beta-D-glucofuranosylthymine, 3,5,6-bicyclophosphite-1-beta-D-glucofuranosyl-5-flurouracil) were prepared. The structure of the new complexes was confirmed by the spectroscopic technique (H-1, P-31{H-1} NMR) and mass spectrometry, and purity by elemental analysis. The molecular structure of the complex with the isopropylidene protection group was established by the X-ray analysis. The antiproliferative activity of the new iridium compounds was evaluated against several cancer cell lines of human origin, and all compounds showed low toxicity independent of the pyrimidine base nature, attached to the sugar unit.

引用

页数：10

共 38 条

[1] Platinum group antitumor chemistry: Design and development of new anticancer drugs complementary to cisplatin
Abu-Surrah, AS
Kettunen, M
[J]. CURRENT MEDICINAL CHEMISTRY, 2006, 13 (11) : 1337 - 1357
[2] Classical and non-classical ruthenium-based anticancer drugs: Towards targeted chemotherapy
Ang, Wee Han
Dyson, Paul J.
[J]. EUROPEAN JOURNAL OF INORGANIC CHEMISTRY, 2006, (20) : 4003 - 4018
[3] Armarego W.L. F., 2003, PURIFICATION LAB CHE, V5th, P608
[4] In Vitro Anticancer Activity and Biologically Relevant Metabolization of Organometallic Ruthenium Complexes with Carbohydrate-Based Ligands
Berger, Isabella
Hanif, Muhammad
Nazarov, Alexey A.
Hartinger, Christian G.
John, Roland O.
Kuznetsov, Maxim L.
Groessl, Michael
Schmitt, Frederic
Zava, Olivier
Biba, Florian
Arion, Vladimir B.
Galanski, Markus
Jakupec, Michael A.
Juillerat-Jeanneret, Lucienne
Dyson, Paul J.
Keppler, Bernhard K.
[J]. CHEMISTRY-A EUROPEAN JOURNAL, 2008, 14 (29) : 9046 - 9057
[5] Cytotoxic platinum coordination compounds. DNA binding agents
Brabec, Viktor
Hrabina, Ondrej
Kasparkova, Jana
[J]. COORDINATION CHEMISTRY REVIEWS, 2017, 351 : 2 - 31
[6] A Phase 1 dose-escalation trial of glufosfamide in combination with gemcitabine in solid tumors including pancreatic adenocarcinoma
Chiorean, E. Gabriela
Dragovich, Tomislav
Hamm, John
Langmuir, Virginia K.
Kroll, Stewart
Jung, Donald T.
Colowick, Alan B.
Tidmarsh, George F.
Loehrer, Patrick J.
[J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2008, 61 (06) : 1019 - 1026
[7] Metal-based antitumour drugs in the post genomic era
Dyson, PJ
Sava, G
[J]. DALTON TRANSACTIONS, 2006, (16) : 1929 - 1933
[8] A Bioorganometallic Chemistry Overview: From Cytochrome P450 Enzyme Metabolism of Organotin Compounds to Organorhodium-Hydroxytamoxifen Complexes with Potential Anti-Cancer Properties; A 37 Year Perspective at the Interface of Organometallic Chemistry and Biology
Fish, Richard H.
[J]. AUSTRALIAN JOURNAL OF CHEMISTRY, 2010, 63 (11) : 1505 - 1513
[9] Florea Ana-Maria, 2011, Cancers (Basel), V3, P1351, DOI 10.3390/cancers3011351
[10] FORNARI FA, 1994, MOL PHARMACOL, V45, P649

← 1 2 3 4 →